AMAG Pharmaceuticals (AMAG) : Greywolf Capital Management Lp added new position in AMAG Pharmaceuticals during the most recent quarter end. The investment management firm now holds 662,330 shares of AMAG Pharmaceuticals which is valued at $16,187,345 , the company said in a statement filed on Aug 15, 2016 with the SEC.AMAG Pharmaceuticals makes up approximately 10.71% of Greywolf Capital Management Lp’s portfolio.
Other Hedge Funds, Including , Price T Rowe Associates Inc Md boosted its stake in AMAG in the latest quarter, The investment management firm added 13,120 additional shares and now holds a total of 533,500 shares of AMAG Pharmaceuticals which is valued at $13,038,740.Janus Capital Management boosted its stake in AMAG in the latest quarter, The investment management firm added 538,322 additional shares and now holds a total of 3,222,639 shares of AMAG Pharmaceuticals which is valued at $78,761,297. AMAG Pharmaceuticals makes up approx 0.06% of Janus Capital Management’s portfolio. Westfield Capital Management Co Lp sold out all of its stake in AMAG during the most recent quarter. The investment firm sold 489,105 shares of AMAG which is valued $11,953,726. Acadian Asset Management added AMAG to its portfolio by purchasing 3,743 company shares during the most recent quarter which is valued at $100,125.
AMAG Pharmaceuticals closed down -0.12 points or -0.50% at $23.71 with 4,28,947 shares getting traded on Thursday. Post opening the session at $23.77, the shares hit an intraday low of $23.48 and an intraday high of $23.94 and the price fluctuated in this range throughout the day.Shares ended Thursday session in Red.
On the company’s financial health, AMAG Pharmaceuticals reported $1.45 EPS for the quarter, beating the analyst consensus estimate by $ 0.25 according to the earnings call on Aug 9, 2016. Analyst had a consensus of $1.20. The company had revenue of $132.50 million for the quarter, compared to analysts expectations of $122.96 million. The company’s revenue was up 46.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.12 EPS.
AMAG Pharmaceuticals Inc. is a specialty pharmaceutical company. The Company focuses on maternal health anemia and cancer supportive care. The Company markets Makena (hydroxyprogesterone caproate injection) Feraheme (ferumoxytol) Injection for Intravenous (IV) use and MuGard Mucoadhesive Oral Wound Rinse. Feraheme is an IV iron replacement therapy for the treatment of iron deficiency anemia (IDA) in adult patients with chronic kidney disease (CKD). Feraheme is approved for marketing in the United States. Makena is a drug indicated to reduce the risk of preterm birth in women with a singleton pregnancy who have a history of singleton spontaneous preterm birth. MuGard is indicated for the management of oral mucositis/stomatitis and all types of oral wounds including aphthous ulcers/canker sores and traumatic ulcers such as those caused by oral surgery or ill-fitting dentures or braces.